Vektor Medical's vMap Tech Promises Zero-Radiation AF Ablation

BOSTON, MA – February 05, 2026 – A significant leap forward in cardiac arrhythmia treatment is taking center stage at the AF Symposium 2026, as San Diego-based Vektor Medical unveils compelling new data for its vMap system. Early results from a real-world registry suggest that complex heart procedures for atrial fibrillation (AF) can now be performed faster and, remarkably, with a median of zero radiation exposure, signaling a potential paradigm shift in patient and clinician safety.

The findings, drawn from the multicenter VITAL-EP Registry, demonstrate that the company's AI-powered, non-invasive technology can guide cardiac ablations with unprecedented efficiency and safety. This development, coupled with the announcement of new capabilities for mapping atrial flutter, positions the vMap platform as a comprehensive tool poised to redefine the standard of care for millions of patients suffering from common heart rhythm disorders.

A New Era of Safety: The Zero-Fluoroscopy Workflow

For decades, fluoroscopy—a continuous X-ray beam—has been an indispensable tool for guiding catheters during cardiac ablation procedures. However, it comes with the inherent risk of radiation exposure for both the patient on the table and the medical team in the electrophysiology (EP) lab. Vektor Medical's latest data suggests this long-standing trade-off may be nearing an end.

The VITAL-EP Registry results highlight a median fluoroscopy time of zero minutes for PVI+ (pulmonary vein isolation plus) procedures across all types of AF, from paroxysmal to longstanding persistent cases. This achievement in eliminating radiation is paired with dramatic gains in efficiency. The median procedure time was approximately 70 minutes, with the critical arrhythmia mapping phase completed in under 10 minutes. By contrast, traditional invasive mapping systems can require significantly longer times and typically involve notable fluoroscopy use.

“These early results show that vMap can meaningfully enhance procedural efficiency while maintaining an exceptionally low fluoroscopy footprint,” said Saumil Oza, MD, in a statement released by the company. “For patients, this means safer procedures. For electrophysiologists, it means faster mapping and a clearer path to confident decision-making in the lab.”

The strong safety profile reported in the registry, alongside high rates of arrhythmia termination during the procedure and post-ablation non-inducibility, underscores the clinical potential of a zero-fluoro workflow. By reducing reliance on radiation, hospitals can create a safer work environment, potentially lowering long-term health risks for their highly specialized staff and offering a less invasive option for patients.

AI-Powered Precision: How vMap Transforms Arrhythmia Care

The engine behind these impressive results is vMap's unique approach to arrhythmia analysis. It is currently the only system with both FDA clearance and European CE-mark approval to use artificial intelligence to transform data from a standard, non-invasive 12-lead electrocardiogram (ECG) into a detailed, three-dimensional map of the heart's electrical activity. This process, which takes less than a minute, pinpoints the sources, or "drivers," that sustain an arrhythmia.

By providing this actionable intelligence before an invasive procedure begins, the technology allows electrophysiologists to plan a more precise and personalized ablation strategy. This contrasts with conventional methods that often involve extensive exploratory mapping with catheters inside the heart to find the problematic tissue. The ability to identify these drivers non-invasively is a key differentiator, helping clinicians move beyond standard PVI to target patient-specific sources of AF.

“These early VITAL-EP results demonstrate the real-world impact vMap can have in driving faster, smarter ablation strategies,” said Rob Krummen, CEO of Vektor Medical. “We’re excited to engage with colleagues at AF Symposium on how non-invasive ECG-based arrhythmia analysis... is giving electrophysiologists clearer insight into cardiac arrhythmias and supporting more confident, patient-centered treatment planning.”

This confidence is being shared with the broader medical community at the symposium. In a spotlight session, Dr. Sei Iwai from Westchester Medical Center Health Network is presenting his clinical experience using vMap to guide comprehensive ablation strategies, illustrating how the technology provides actionable insights that can inform treatment beyond the standard approach.

Beyond Atrial Fibrillation: Expanding the Diagnostic Horizon

Building on its success in AF, Vektor Medical also announced an expansion of the vMap platform to include a new workflow for atrial flutter, another common arrhythmia. This update enables the system to non-invasively distinguish between typical and atypical forms of atrial flutter using only a 12-lead ECG. This distinction is critical, as the two types originate in different parts of the atrium and require different ablation strategies.

This expansion transforms vMap from a specialized AF tool into a more versatile diagnostic and planning platform for a broader range of arrhythmias. Clinicians can now use a single, non-invasive system to evaluate patients with either of the two most common atrial arrhythmias, streamlining the diagnostic process and facilitating more comprehensive treatment planning from the outset. This integrated approach promises to reduce redundant testing and shorten the time from diagnosis to effective treatment.

From Lab to Market: Vektor's Path to a New Standard

Founded in 2017, Vektor Medical has moved with strategic purpose to bring its innovation from the research lab to the clinical front line. The company's technology secured FDA clearance in late 2021 and, more recently, a CE Mark under Europe's stringent new Medical Device Regulation (MDR) in October 2025, opening the door to global markets.

This progress is backed by significant investor confidence. In early 2024, the company closed a $28.9 million Series A funding round co-led by Solas BioVentures and TVM Capital Life Science. The capital is fueling the technology's commercial launch, market expansion in the U.S. and Europe, and further clinical research to solidify its value proposition.

To that end, the company is not resting on the early results of the VITAL-EP registry. It has also initiated the IMPRoVED AF study, a large-scale, prospective, randomized controlled trial that will compare outcomes for patients receiving standard PVI alone versus those receiving PVI plus vMap-guided driver ablation. With interim results anticipated in 2026, this landmark study is designed to generate the highest level of clinical evidence, paving the way for broad adoption and, crucially, reimbursement from payers. This commitment to rigorous validation underscores the company's strategy to establish vMap as an essential tool in the modern EP lab.